Van Crocker has spent his 20+ year career driving innovation and change in the healthcare field, both in senior operating roles and as a management consultant. Currently, Van is President and Founder of Agonist Health, a strategic consulting organization specializing in decentralized clinical research and real world evidence. Agonist maintains multiple senior advisory and client relationships for companies that innovate in these emerging industry sectors. In 2020-21, Van co-founded and led Vidence (a spin-off of cancer hospital system CTCA) as its CEO, navigating the real world evidence company through the COVID pandemic. From 2013-2020, Van was President of Healthagen, the life sciences division of Aetna/CVS, harnessing large scale health data for AI/machine learning applications, decentralized clinical trials, and digital health. Healthagen is now known as CVS Clinical Trial Services. Prior to Healthagen, Van led finance and business development for Exicure, a biotechnology company funded by AbbVie and Bill Gates. The company and its affiliates have developed a broad array of nanoparticle-based genetic therapies and diagnostic platforms, with applications including cancer and rare diseases. Prior to Exicure, Van was a management consultant with Booz & Company, focusing on strategic transactions and initiatives for payer/provider clients. Van holds a B.S. from the University of Virginia and an M.B.A. (Honors) from Kellogg. He began his career in software services with Oracle Corporation.